Adial Historical Cash Flow
| ADIL Stock | USD 1.09 0.01 0.91% |
Analysis of Adial Pharmaceuticals cash flow over time is an excellent tool to project Adial Pharmaceuticals future capital expenditures as well as to predict the amount of cash needed to cover cost of sales, R&D expenses or production expansions. Investors should almost always look for trends in cash flow indicators such as Stock Based Compensation of 2.3 M or Begin Period Cash Flow of 3.2 M as it is a great indicator of Adial Pharmaceuticals ability to facilitate future growth, repay debt on time or pay out dividends.
Financial Statement Analysis is much more than just reviewing and examining Adial Pharmaceuticals latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Adial Pharmaceuticals is a good buy for the upcoming year.
Adial |
About Adial Cash Flow Analysis
The Cash Flow Statement is a financial statement that shows how changes in Adial balance sheet and income statement accounts affect cash and cash equivalents. It breaks the analysis down to operating, investing, and financing activities. One of the most critical aspects of the cash flow statement is liquidity, which is the degree to which Adial's non-liquid assets can be easily converted into cash.
Adial Pharmaceuticals Cash Flow Chart
Add Fundamental
Net Borrowings
The difference between the amount of new debt a company has taken on and the amount of debt it has paid off during a given period.Stock Based Compensation
Compensation provided to employees in the form of equity or options to purchase company stock. This type of compensation is used to align the interests of employees and shareholders.Begin Period Cash Flow
The amount of cash a company has at the beginning of a financial reporting period. It serves as the starting point for calculating the period's cash flow from operations, investing, and financing activities.Most accounts from Adial Pharmaceuticals' cash flow statement are interrelated and interconnected. However, analyzing cash flow statement accounts one by one will only give a small insight into Adial Pharmaceuticals current financial condition. On the other hand, looking into the entire matrix of cash flow statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Adial Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product. For more information on how to buy Adial Stock please use our How to buy in Adial Stock guide.At this time, Adial Pharmaceuticals' Change To Netincome is quite stable compared to the past year. Investments is expected to rise to about 1.2 M this year, although the value of Change In Cash is projected to rise to (1.1 M).
| 2023 | 2024 (projected) | Stock Based Compensation | 1.7M | 2.3M | Net Borrowings | 22.5K | 21.4K |
Adial Pharmaceuticals cash flow statement Correlations
Click cells to compare fundamentals
Adial Pharmaceuticals Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Adial Pharmaceuticals cash flow statement Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Sale Purchase Of Stock | 6.4M | 9.2M | 5.6M | (1.7K) | (1.9K) | (1.8K) | |
| Change In Cash | 2.9M | (2.4M) | 1.7M | (2.1M) | (1.2M) | (1.1M) | |
| Stock Based Compensation | 1.6M | 2.0M | 4.2M | 3.4M | 1.7M | 2.3M | |
| Free Cash Flow | (6.3M) | (7.6M) | (12.0M) | (11.2M) | (6.8M) | (7.1M) | |
| Change In Working Capital | 208.2K | 1.2M | 1.5M | (1.4M) | (794.2K) | (754.5K) | |
| Begin Period Cash Flow | 3.9M | 6.8M | 4.4M | 6.1M | 4.0M | 3.2M | |
| Other Cashflows From Financing Activities | 1.1M | 450.0K | 1.9M | 1.9K | 1.5M | 1.6M | |
| Other Non Cash Items | 441.8K | 1.6M | 1.8M | (522K) | 1.1M | 692.5K | |
| Total Cash From Operating Activities | (6.3M) | (7.6M) | (11.9M) | (11.2M) | (6.8M) | (7.1M) | |
| Change To Operating Activities | (658.8K) | 117.6K | 786.5K | 1.5M | 1.7M | 1.8M | |
| Net Income | (8.6M) | (10.9M) | (19.4M) | (12.7M) | (7.0M) | (7.4M) | |
| Total Cash From Financing Activities | 9.2M | 5.6M | 13.6M | 9.1M | 4.1M | 6.0M | |
| End Period Cash Flow | 6.8M | 4.4M | 6.1M | 4.0M | 2.8M | 3.4M | |
| Change To Netincome | 9.6M | 1.6M | 2.0M | 6.0M | 6.8M | 7.2M | |
| Change To Liabilities | (34.8K) | 281.1K | 458.5K | (353.8K) | (318.4K) | (302.5K) | |
| Issuance Of Capital Stock | 8.2M | 5.2M | 11.8M | 9.1M | 749.9K | 712.4K |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Trending Equities to better understand how to build diversified portfolios, which includes a position in Adial Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product. For more information on how to buy Adial Stock please use our How to buy in Adial Stock guide.You can also try the Odds Of Bankruptcy module to get analysis of equity chance of financial distress in the next 2 years.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Adial Pharmaceuticals. If investors know Adial will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Adial Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.94) | Return On Assets (1.04) | Return On Equity (3.21) |
The market value of Adial Pharmaceuticals is measured differently than its book value, which is the value of Adial that is recorded on the company's balance sheet. Investors also form their own opinion of Adial Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Adial Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Adial Pharmaceuticals' market value can be influenced by many factors that don't directly affect Adial Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Adial Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Adial Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Adial Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.